April 13 (Reuters) - Bausch Health Companies Inc BHC.TO :
* BAUSCH HEALTH INITIATES VIRAZOLE (RIBAVIRIN FOR INHALATION SOLUTION, USP) CLINICAL STUDY IN PATIENTS WITH COVID-19
* BAUSCH HEALTH COMPANIES INC - WORKING WITH MULTIPLE HEALTH AUTHORITIES TO MAKE VIRAZOLE AVAILABLE AS A POTENTIAL TREATMENT FOR COVID-19
* BAUSCH HEALTH COMPANIES INC - INITIAL VIRAZOLE CLINICAL STUDY HAS BEEN APPROVED BY HEALTH CANADA AND IS EXPECTED TO BEGIN WITHIN NEXT FEW WEEKS